Natera (NASDAQ:NTRA) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Natera (NASDAQ:NTRA) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

NTRA has been the subject of several other reports. BidaskClub raised shares of Natera from a buy rating to a strong-buy rating in a report on Tuesday, October 8th. JPMorgan Chase & Co. raised their price objective on shares of Natera from $27.00 to $32.00 and gave the stock a neutral rating in a report on Monday, November 4th. Craig Hallum raised their price objective on shares of Natera from $37.00 to $49.00 and gave the stock a buy rating in a report on Thursday, November 7th. ValuEngine raised shares of Natera from a hold rating to a buy rating in a report on Friday, November 1st. Finally, Canaccord Genuity reissued a buy rating and set a $44.00 price objective on shares of Natera in a report on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Natera presently has an average rating of Buy and an average price target of $42.50.

NASDAQ NTRA traded up $1.52 during mid-day trading on Tuesday, reaching $39.83. 422,300 shares of the stock were exchanged, compared to its average volume of 742,237. The stock has a market capitalization of $3.06 billion, a PE ratio of -18.53 and a beta of 1.45. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.42 and a current ratio of 2.35. Natera has a 1-year low of $11.08 and a 1-year high of $40.92. The business’s fifty day simple moving average is $36.87 and its 200 day simple moving average is $29.24.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.20. The company had revenue of $77.90 million during the quarter, compared to analyst estimates of $73.97 million. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the business earned ($0.49) EPS. On average, analysts anticipate that Natera will post -2.15 EPS for the current year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, CFO Michael Burkes Brophy sold 2,859 shares of Natera stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $38.25, for a total value of $109,356.75. Following the completion of the transaction, the chief financial officer now directly owns 16,630 shares of the company’s stock, valued at approximately $636,097.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Jonathan Sheena sold 1,033 shares of Natera stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $29.50, for a total transaction of $30,473.50. Following the completion of the transaction, the chief technology officer now directly owns 241,937 shares of the company’s stock, valued at $7,137,141.50. The disclosure for this sale can be found here. Insiders sold a total of 64,557 shares of company stock valued at $2,241,958 over the last ninety days. Company insiders own 9.29% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. TD Asset Management Inc. bought a new stake in Natera in the 2nd quarter valued at about $477,000. Cubist Systematic Strategies LLC lifted its position in Natera by 44.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 36,381 shares of the medical research company’s stock valued at $1,003,000 after purchasing an additional 11,221 shares during the last quarter. Asymmetry Capital Management L.P. lifted its position in Natera by 615.4% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 217,899 shares of the medical research company’s stock valued at $6,010,000 after purchasing an additional 187,441 shares during the last quarter. Allianz Asset Management GmbH lifted its position in Natera by 4.5% in the 2nd quarter. Allianz Asset Management GmbH now owns 589,036 shares of the medical research company’s stock valued at $16,246,000 after purchasing an additional 25,334 shares during the last quarter. Finally, Dupont Capital Management Corp lifted its position in Natera by 78.6% in the 2nd quarter. Dupont Capital Management Corp now owns 51,953 shares of the medical research company’s stock valued at $1,433,000 after purchasing an additional 22,866 shares during the last quarter. 95.53% of the stock is owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: Different Options Trading Strategies

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Leave a Reply

Your email address will not be published. Required fields are marked *

*